KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Total Liabilities (2016 - 2025)

Historic Total Liabilities for West Pharmaceutical Services (WST) over the last 17 years, with Q3 2025 value amounting to $1.1 billion.

  • West Pharmaceutical Services' Total Liabilities rose 1422.54% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 1422.54%. This contributed to the annual value of $961.1 million for FY2024, which is 132.84% up from last year.
  • West Pharmaceutical Services' Total Liabilities amounted to $1.1 billion in Q3 2025, which was up 1422.54% from $1.0 billion recorded in Q2 2025.
  • West Pharmaceutical Services' Total Liabilities' 5-year high stood at $1.1 billion during Q3 2025, with a 5-year trough of $846.0 million in Q3 2022.
  • For the 5-year period, West Pharmaceutical Services' Total Liabilities averaged around $939.5 million, with its median value being $935.1 million (2025).
  • In the last 5 years, West Pharmaceutical Services' Total Liabilities skyrocketed by 2041.52% in 2021 and then plummeted by 1002.87% in 2022.
  • Over the past 5 years, West Pharmaceutical Services' Total Liabilities (Quarter) stood at $978.4 million in 2021, then dropped by 4.75% to $931.9 million in 2022, then increased by 1.78% to $948.5 million in 2023, then increased by 1.33% to $961.1 million in 2024, then grew by 9.7% to $1.1 billion in 2025.
  • Its Total Liabilities stands at $1.1 billion for Q3 2025, versus $1.0 billion for Q2 2025 and $935.1 million for Q1 2025.